NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

Surgery Partners, Inc. Announces Commencement of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032

25m ago🟡 Routine Noise
Share𝕏inf

Surgery Partners seeks noteholder consent to ease merger terms on $1.225 billion debt.

What the company is saying

Surgery Partners, Inc. is informing investors that its subsidiary, Surgery Center Holdings, Inc., has launched a consent solicitation for the $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032. The company emphasizes that the solicitation aims to amend the indenture so Bon Secours Mercy Health, Inc. (BSMH), HealthSpan Partners, and their affiliates become 'Permitted Holders,' facilitating the pending merger with Spyglass Topco, LLC. The announcement highlights the mechanics: holders of record as of November 20, 2026, can deliver consents by 5:00 p.m. that day, and those who participate and are accepted will receive a cash payment of $2.50 per $1,000 in principal. Surgery Partners is clear that if the amendments are not adopted, the merger would trigger a 'Change of Control,' requiring a repurchase of all notes at 101% of principal plus accrued interest. The company underscores that all other note terms, including the 7.250% interest rate and 2032 maturity, remain unchanged. The tone is procedural and neutral, focusing on the consent process, eligibility, and the consequences for noteholders.

What the data suggests

The company has $1,225,000,000 in 7.250% Senior Notes due 2032 outstanding, and is seeking majority noteholder consent for amendments to the indenture. The consent fee offered is $2.50 per $1,000 in principal, payable only to holders who timely consent and are accepted. If the amendments are not operative, the merger would require Surgery Center Holdings, Inc. to offer to buy all notes at 101% of principal plus accrued and unpaid interest. The consent solicitation expires at 5:00 p.m. New York City time on November 20, 2026, with only holders of record at that time eligible. The merger is expected to close in the first quarter of 2027, subject to shareholder and regulatory approvals. The process is governed by a Consent Solicitation Statement, and the company has named Jefferies LLC as solicitation agent and S&P Global Inc. as information and tabulation agent. No operational or financial performance metrics are disclosed beyond the debt principal, interest rate, and consent fee.

Analysis

The announcement is a factual, procedural disclosure regarding a consent solicitation tied to a pending merger and the treatment of $1.225 billion in senior notes. The language is strictly descriptive, outlining the mechanics, eligibility, and consequences for noteholders, with no promotional or exaggerated claims about future benefits or operational synergies. While some forward-looking statements are present (e.g., the merger is expected to close in Q1 2027, subject to approvals), these are standard for such transactions and are not presented as guaranteed outcomes. There is no attempt to frame the transaction as immediately value-accretive or to overstate its impact. The capital intensity is high due to the large principal amount of notes, but the announcement does not hype potential returns or benefits. No profitability, revenue, or operational growth claims are made, and the tone remains neutral throughout.

Risk flags

  • ●There is execution risk that the company may not obtain the required majority consents from noteholders, which would trigger a mandatory offer to repurchase all notes at 101% of principal plus accrued interest if the merger proceeds. This could create a significant liquidity requirement and potentially disrupt the merger timeline.
  • ●The merger's completion is subject to Surgery Partners' stockholder approval, regulatory approvals, and other customary closing conditions, any of which could delay or prevent closing. The announcement does not specify the likelihood or status of these approvals, leaving uncertainty around deal closure.
  • ●If the consent fee is paid but the merger does not close within five business days after the end date, the amendments will not become operative, but holders who received the consent fee will retain it. This creates a scenario where the company pays out cash without achieving the intended amendment, resulting in a potential cost with no structural benefit.
  • ●The announcement does not provide any information on the company's current financial position, liquidity, or ability to fund a potential Change of Control Offer, leaving investors without visibility into the company's capacity to manage a forced repurchase of $1.225 billion in notes.

Bottom line

Surgery Partners is seeking noteholder consent to amend the indenture on $1,225,000,000 of 7.250% Senior Notes due 2032, aiming to facilitate its merger with Spyglass Topco, LLC by making BSMH and affiliates 'Permitted Holders.' The process is time-sensitive, with the consent deadline on November 20, 2026, and the merger targeted for the first quarter of 2027. If consents are not obtained, the company would be forced to offer to repurchase all notes at 101% of principal plus accrued interest, a potentially material cash outlay. The consent fee of $2.50 per $1,000 is a modest incentive, and the company provides no operational or financial updates beyond the transaction mechanics. Investors should focus on the risk that the amendments may not be approved, which could complicate or increase the cost of the merger. The most important takeaway is that the outcome of this consent solicitation will directly affect the financial and structural path of the pending merger.

Announcement summary

(NASDAQ:SGRY) Surgery Partners, Inc. announced that its indirect wholly owned subsidiary, Surgery Center Holdings, Inc., has commenced a consent solicitation from holders of its outstanding $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032. The consent solicitation seeks approval for proposed amendments to the indenture governing the Notes, dated as of April 10, 2024, to designate Bon Secours Mercy Health, Inc. (BSMH), HealthSpan Partners, and their affiliates as 'Permitted Holders' under the indenture, in addition to existing Permitted Holders, and to amend certain related defined terms. The solicitation is being made in connection with the previously announced Agreement and Plan of Merger, under which Spyglass Merger Subsidiary, Inc. will merge with and into Surgery Partners, with Surgery Partners surviving as a wholly owned subsidiary of Spyglass Topco, LLC. If the proposed amendments are not operative, the consummation of the merger would constitute a 'Change of Control' under the indenture, requiring the issuer to offer to purchase all outstanding Notes at 101% of principal plus accrued and unpaid interest. Holders of record as of 5:00 p.m., New York City time, on November 20, 2026, are eligible to deliver consents, and the consent solicitation is scheduled to expire at 5:00 p.m., New York City time, on November 20, 2026, unless extended or earlier terminated. Holders who validly deliver and do not revoke consents prior to the expiration time, and whose consents are accepted, will be eligible to receive a cash payment equal to $2.50 per $1,000 in principal amount of Notes for which consents were delivered, subject to satisfaction or waiver of conditions including receipt of requisite consents. The proposed amendments require the consent of holders of a majority of the aggregate principal amount of the Notes outstanding. The supplemental indenture will become effective upon execution but operative only immediately prior to the consummation of the merger, provided the consent fee has been paid. If the consent fee is paid but the merger is not consummated within five business days after the end date, the amendments will not become operative, and holders who received the consent fee will retain it. The merger is expected to close in the first quarter of 2027, subject to Surgery Partners’ stockholder approval, required regulatory approvals, and other customary closing conditions. Jefferies LLC is serving as solicitation agent, and S&P Global Inc. is serving as information and tabulation agent for the consent solicitation. The complete terms and conditions are set forth in the Consent Solicitation Statement dated November 16, 2026.

Disagree with this article?

Ctrl + Enter to submit